Clinical Trials Logo
  1. Home
  2. Adenocarcinoma of the Stomach
  3. NCT05970627

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach Clinical Trial

Official title:
Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II Study

Clinical Trial Summary

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05970627
Study type Interventional
Source First Affiliated Hospital of Zhejiang University
Contact Jiren Yu
Phone 0086-0571-87237931
Email yujr0909@zju.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date July 28, 2023
Completion date July 28, 2029
View Details
See also
  Status Clinical Trial Phase
Completed NCT00982592 - Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT04077255 - EGFR-targeted Therapy for Gastric Cancer Phase 2
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT00098527 - FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Active, not recruiting NCT03647969 - Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer Phase 2
Terminated NCT00871273 - Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Phase 4
Recruiting NCT05729646 - Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT05315830 - A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric Phase 1
Active, not recruiting NCT01095120 - Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer Phase 2
Completed NCT00062374 - Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction Phase 2
Active, not recruiting NCT02202759 - A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction Phase 2
Recruiting NCT01962519 - Early Oral Feeding After Total Gastrectomy for Cancer N/A
Completed NCT00607594 - Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT06121700 - Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer Phase 2
Terminated NCT03722108 - Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas Phase 1/Phase 2
Recruiting NCT05715931 - Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT02678182 - Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial Phase 2
Completed NCT01640782 - Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Phase 3
Recruiting NCT05872685 - Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) Phase 2